flanders.bio is an independent life sciences cluster organisation based in Flanders, Belgium

flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise. flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.

News from flanders.bio and its members

More stringent application of EU rules, affecting eligibility for grants & subsidies

We have recently been contacted by a number of member companies that have been confronted with difficulties when submitting an R&D project proposal at VLAIO (Flemish R&D Grant office). Since 1/10/2017 VLAIO conformed its internal evaluation criteria for grant funding with the European guidelines on State aid for rescuing and restructuring firms in difficulty.

Finance | 23 November 17 Read more

Galapagos NV - Transparency notification

Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Fidelity Management & Research (FMR) LLC.

Finance | 12 December 17 Read more

argenx announces launch of proposed public offering in the United States

argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today that it has commenced an underwritten U.S. public offering of $150 million of its American Depositary Shares (ADSs) (the Offering). Each of the ADSs offered in the Offering represents the right to receive one ordinary share, nominal value of €0.10 per share. All of the ADSs in the proposed Offering are to be sold by argenx.

Finance | 12 December 17 Read more

New start-up Aelin Therapeutics secures 27M Euros to pioneer the development of a novel drug modality

Leuven (Belgium), December 11, 2017 - Aelin Therapeutics, a privately held Belgian biotherapeutics company, announces today that it has secured a 27 M€ investment to pioneer a novel modality in drug development in order to create a completely new class of antibiotics and first-in-class therapeutics against high-value undruggable human targets. The technology, branded Pept-ins™, harnesses the power of protein aggregation to specifically induce functional knockdown of a target protein. The company will use the proceeds of the 27 M€ Series A financing, to bring a first Pept-in product to the clinic.

Finance | 11 December 17 Read more

Galapagos to enter NASDAQ Biotech Index

Galapagos NV (Euronext & NASDAQ: GLPG) announces that it will be included in NASDAQ Biotech Index on NASDAQ, effective 18 December 2017.

Stock Market | 11 December 17 Read more

flanders.bio events, trainings & international missions

Alternate Text

22/02/2018 - OPINNO BioBizz Café Ghent

flanders.bio offers students in life sciences (bachelor, master, PhD) the unique opportunity to meet representatives from life sciences companies during the OPINNO BioBizz Cafés. We are organising 3 Cafés: 1 in Ghent, 1 in Leuven and 1 in Antwerp.

Strategic Partners